Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Patent
1999-02-24
2000-10-24
McKelvey, Terry
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
4242151, A61K 3915
Patent
active
061363073
ABSTRACT:
Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
G. Hashiro et al., "The Preferential Cytotoxicity of Reovirus for certain transformed cell lines", Archives of Virology 54(4):307-315 (1977).
J.E. Strong et al., "The Molecular Basis of Viral Oncolysis: Usurption of the Ras signaling Pathway by Reovirus", The EMBO Journal 17(12):3351-3362 (Jun. 15, 1998).
Tang et al., "Short communications: Recognitiion of the Epidermal Growth Factor Reeptor by Reovirus" Virology 197:412-414 (1993).
Sharp et al., "Homologous regions of the .alpha. subunit of eukaryotic translational initiation factor 2 (eIF2.alpha.) and the vaccinia virus K3L gene produt interact with the same domain within the dsRNA-activated protein kinase (PKR)" Eur. J. Biochem. 250:85-91 (1997).
Randazzo et al., "Herpes Simplex virus 1716, and ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40" J. of Gen. Virol. 78:3333-3339 (1997).
He et al., "Suppression of the phenotype of .gamma.1 34.5- herpes simplex 1: Failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the .alpha.47 Gene" J. of Virol. 71(8):6049-6054 (Aug. 1997).
Gale, Jr. et al., "Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein" Virology 230:217-227 (1997).
Kawagishi-Kobayashi et al., "Regulation of the protein kinase PKR by the vaccinia viurs pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the pKR substrate 3IF2.alpha." Mol. and Cell Biol. 17(7):4146-4158 (1997).
Cahill, M. A., et al., "Signalling pathways: Jack of all cascades," Current Biology, 6(1): 16-19 (1996).
Macara, I. G., et al., "The Ras superfamily og GTPases," The FASEB Journal, 10: 625-630 (1996).
Marshall, C. J., "Ras effectors," Current Opinion in Cell Biology, 8:197-204 (1996).
Strong, J. E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency," Virol. 197:405-411 (1993).
Duncan, M. R., et al., "Differential Sensivivity of Normal and Transformed Human Cells to Reovirus Infection," J. of Virol. 28 (2):444-449 (1978).
Soroceanu, L. et al., "Use of Genetically Engineered HSV-1 Viruses in Treatment of Malignant Intracerebral Gliomas," FASEB.J. 9(3): Abstract 812 p. A139 (1995).
Andreansky, S.S. et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).
Boviatsis, E.J., et al., "Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase," Gene Therapy 1:323-331 (1994).
Taterka, J. et al., "Characterization of Cytotoxic Cells from Reovirus-Infected SCID Mice: Activated Cells Express Natural Killer-and Lymphokine-Activated Killer-Like Activity but Fall to Clear Infection," J. of Virol. 69 (6): 3910-3914 (1995).
Zhang, J.F., et al., "Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy," Proc. natl. Acad. Sci. USA 93:4513-4518 (1996).
Chambers, R. et al., "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma," Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995).
Williams, M.E. et al., "Rejectin of reovirus-treated L1210 leukemia cells by mice," Cancer Immunol. Immunother. 23:87-92 (1986).
Theiss, J.C. et al., "Effect of Reovirus Infection on Pulmonary Tumor Response to Urethan in Strain A Mice," J. Natl. Cancer Inst 61:131-134 (1978).
Kollermorgen, G.M. et al., "Immunotherapy of EL4 Lymphoma with Reovirus," Cancer Immunol. Immunother. 1:239-244 (1976).
Bryson, J.S. and Cox, D.C., "Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia," Cancer Immunol. Immunother. 26: 132-138 (1988).
Gentsch, J.R. and Pacitti, A.F., Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3.
Strong, J.E. et al., "Evidence That the Epidermal Growth Factor Receptor on Host Cells confers Reovirus Infection Efficiency," Virology 197:405-411 (1993).
Hershey, J.W.B., "Translation Cntrol in Mammalian Cells," Annu. Rev. Biochem. 60:717-755 (1991).
Steele et al, Cancer Biotherapy, vol. 10 (4): pp. 307-315, 1995.
Strong et al, Journal of Virology, vol. 70 (1): pp. 612-616, Jan, 1996.
Barbacid, Annu7al Review of Biochemistry, vol. 56: pp. 779-827, 1987.
Coffey Matthew C.
Lee Patrick W. K.
Strong James
McKelvey Terry
Oncolytics Biotech Inc.
LandOfFree
Reovirus for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1960589